ClinicalTrials.gg

Program

Cilostazol

Also written as “Cilostazol 100 mg”, “Cilostazol 50 mg Tablets” and “Cilostazol Tablet 100 mg”.

Its studies are mostly in Intermittent Claudication · Cerebral Infarction · Angina Pectoris, Variant · Raynaud Disease · Hypercholesterolemia, led by 7 companies.

Furthest: phase 4, since Nov 7, 200229 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka160 open or runningphase 4since Nov 7, 2002Nov 7, 2002none ahead
Genovate Biotechnology50 open or runningphase 3since Mar 13, 2025Mar 5, 2019none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Mutual Pharmaceutical20 open or runningphase 1since May 24, 2008May 24, 2008none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Feb 5, 2009Feb 5, 2009none ahead
Novartis10 open or runningphase 1since Apr 13, 2009Apr 13, 2009none ahead
Viatris10 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead

Also a collaborator on its studies: zhejiang-otsuka-pharmaceutical-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Nov 7, 2002.

  1. Jan 14, 20092 phase 4 studiesOtsuka · NCT00823849, NCT00823875
  2. Feb 5, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00838630, NCT00839930
  3. Apr 13, 2009Novartis's first study: phase 1 study in PainNew to NovartisNovartis · NCT00881231 · 26 enrolled
  4. Feb 24, 2010Phase 4 study in PolyneuropathiesOtsuka · NCT01076478 · 47 enrolled · Philippines
  5. Apr 21, 2010Phase 4 study in Diabetic NephropathiesOtsuka · NCT01252056 · 353 enrolled · China
  6. Jun 10, 2010Phase 2 study in Peripheral Arterial DiseaseOtsuka · NCT01142284 · 80 enrolled · Korea, Republic of
  7. Feb 17, 2014Phase 3 study in Angina Pectoris, VariantOtsuka · NCT02087007 · 100 enrolled · Korea, Republic of
  8. Mar 20, 2014Phase 3 study in Angina Pectoris, VariantOtsuka · NCT02094469 · 65 enrolled · Korea, Republic of
  9. Mar 25, 2014Phase 4 study in HypercholesterolemiaOtsuka · NCT02098460 · 300 enrolled · China
  10. Mar 5, 2019Genovate Biotechnology's first study: phase 1 study in Intermittent ClaudicationNew to Genovate BiotechnologyGenovate Biotechnology · NCT03864666 · 28 enrolled · United States
  11. Dec 10, 2021Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT05191862 · 19 enrolled · United States
  12. Jul 18, 2022Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT05466734 · 25 enrolled · United States
  13. Dec 4, 2023Phase 1 study in Intermittent ClaudicationGenovate Biotechnology · NCT06167265 · 40 enrolled · United States
  14. Mar 13, 2025Phase 3 study in Intermittent ClaudicationGenovate Biotechnology · NCT06886620 · 14 enrolled · Taiwan

TargetBeta

PDE3A →read by rule
“Phosphodiesterase 3A inhibitor”ChEMBL 37, by rule

Other programs on PDE3A

ProgramCompanyFurthest phaseStudies
ensifentrineruleMerckphase 317

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06886620Intermittent Claudication · Taiwan3TerminatedGenovate BiotechnologyFeb 8, 201714
NCT06167265Intermittent Claudication · United States1CompletedGenovate BiotechnologyDec 22, 202340
NCT05466734Intermittent Claudication · United States1CompletedGenovate BiotechnologyAug 23, 202225
NCT05191862Intermittent Claudication · United States1TerminatedGenovate BiotechnologyMay 4, 202219
NCT03864666Intermittent Claudication · United States1CompletedGenovate BiotechnologyMar 19, 201928
NCT02098460Hypercholesterolemia · China4CompletedOtsukaMar 2016300
NCT02094469Angina Pectoris, Variant · Korea, Republic of3CompletedOtsukaJan 201665
NCT02087007Angina Pectoris, Variant · Korea, Republic of3CompletedOtsukaJul 2015100
NCT01142284Peripheral Arterial Disease · Korea, Republic of2CompletedOtsukaNov 29, 201280
NCT01252056Diabetic Nephropathies · China4CompletedOtsukaDec 2012353
NCT01076478Polyneuropathies · Philippines4CompletedOtsuka47
NCT00881231Pain1CompletedNovartisFeb 200426
NCT00839930Healthy · United States1CompletedTeva Pharmaceutical IndustriesFeb 200430
NCT00838630Healthy · United States1CompletedTeva Pharmaceutical IndustriesNov 200336
NCT00823875Atherosclerosis Cerebral Infarction · China4CompletedOtsukaDec 2009200
NCT00823849Diabetes Mellitus, Type 2 · China4CompletedOtsukaAug 2009200
NCT00773630Intermittent Claudication · Germany1CompletedOtsukaMar 200944
NCT00766545Cerebral Infarction · Japan3CompletedOtsukaMar 19971,095
NCT00685802Therapeutic Equivalency, Healthy1CompletedMutual PharmaceuticalJul 200432
NCT00684762Therapeutic Equivalency1CompletedMutual PharmaceuticalMar 200432
NCT00648388Healthy · United States1CompletedViatrisMay 200444
NCT00602407Intermittent Claudication · United States–CompletedHikma PharmaceuticalsMar 200436
NCT00602173Intermittent Claudication · United States–CompletedHikma PharmaceuticalsMay 200332
NCT00549978Healthy · Korea, Republic of4CompletedOtsukaMay 200832
NCT00272454Cerebral Infarction · Korea, Republic of4CompletedOtsuka468
NCT00234065Cerebral Infarction · Japan4CompletedOtsukaDec 20082,800
NCT00202020Cerebral Infarction · China3CompletedOtsuka720
NCT00048776Raynaud Disease · United States4CompletedOtsuka75
NCT00048763Raynaud Disease · United States4CompletedOtsuka75

How it is read

Names in the registry

  • “Cilostazol”, 10 entries
  • “Cilostazol 100 mg”, 3 entries
  • “Cilostazol 50 mg Tablets”, 2 entries
  • “Cilostazol Tablet 100 mg”, 2 entries
  • “Pletal”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.